Vaxcyte

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vaxcyte reports robust Q4 performance and eyes vaccine market growth

Vaxcyte's Q4 performance highlighted strong financials, promising pipeline programs, and strategic market positioning.
The company faces challenges in pediatric efficacy translation, differentiation, and operational scalability.
Opportunities lie in expanding manufacturing, leveraging unique vaccine approaches, and addressing critical medical needs.

Vaxcyte excels in 2023 with strong PCV progress and financial growth

Vaxcyte's strong performance in 2023, with progress in key PCV candidates and financial strength, positions them well in the competitive vaccine market. Challenges include uncertainties in the competitive landscape and adapting to different vaccination schedules globally. Opportunities lie in upcoming milestones, global commercialization, and meeting the demand for broadly protective vaccines.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through the Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering and Jeff Fairman on November 27, 2013, and is headquartered in San Carlos, CA.

Altra Industrial Motion

Carvana

Generac Holdings

Maravai LifeSciences Holdings

Norwegian Cruise Line

Olaplex Holdings

PTC Therapeutics

Patterson-UTI Energy

Mid-cap companies lie in between the slower growth large-cap stocks and the faster-growth small-cap businesses.

These Were The Five Best And Worst Performing Mid-Cap Stocks In October 2022

-- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 --

Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

Not everything is negative in this bearish market. The healthcare sector is home to stocks with rosy prospects.

Vaxcyte Has A Bright Future Ahead

Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.

Why Investors Are Suddenly Excited About Vaxcyte

The company released early data for a promising pneumonia vaccine.

Why Shares of Vaxcyte Rose 110.7% This Week

SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the closing of its previously announced underwritten public offering of 17,812,500 shares of common stock at a public offering price of $32.00 per share and pre-funded warrants to purchase 3,750,000 shares of common stock at a public offering price of $31.999 per underlying share. This includes the exercise in full by the underwriters of their option to purchase up to 2,812,500 additional shares of common stock at the public offering price per share, less underwriting discounts and commissions. The aggregate gross proceeds to Vaxcyte from this offering were approximately $690.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.

Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN CARLOS, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 15,000,000 shares of common stock and pre-funded warrants to purchase 3,750,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $32.00 per share, and the pre-funded warrants are being sold at a public offering price of $31.999 per underlying share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $600.0 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding the exercise of any pre-funded warrants. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Vaxcyte. Vaxcyte has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions.

Vaxcyte Announces Pricing of $600 Million Public Offering

Vaxcyte, Inc. (PCVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Recent Price Trend in Vaxcyte, Inc. (PCVX) is Your Friend, Here's Why

Vaxcyte (NASDAQ: PCVX ) stock is rocketing higher on Monday after the vaccine company revealed positive data from a Phase 1/2 clinical trial. This part of the study handled the safety, tolerability, and immunogenicity of VAX-24.

Why Is Vaxcyte (PCVX) Stock Up 70% Today?

Shares of Vaxcyte Inc. PCVX, -7.42% soared 46.7% in premarket trading on Monday after the company said its experimental 24-valent pneumococcal conjugate vaccine met the primary endpoint in a Phase 1/2 clinical proof-of-concept study. The vaccine was tested in healthy adults.

Vaxcyte's stock rallies 46% on positive data for its pneumococcal vaccine candidate

-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20™ (PCV20) at All Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards --

Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64

SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, October 24, 2022, at 8:00 a.m. Eastern Time to provide topline results from its Phase 1/2 proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's investigational 24-valent pneumococcal conjugate vaccine (PCV), in healthy adults aged 18-64.

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

-- Vaxcyte has Appointed Mark Wiggins, M.B.A. as Chief Business Officer and Jakub Simon M.D., M.S. as Chief Medical Officer as the Company Prepares to Enter Next Phase of Growth -- SAN CARLOS, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer. Both Mark and Jakub are accomplished industry leaders who bring vast expertise that will support the continued growth and advancement of the Company.

Vaxcyte Expands Executive Leadership Team with Key Appointments

-- Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 -- -- Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 --

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

-- Completed Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults -- -- Announcement of Topline Results from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study Expected in October or November 2022 --

Vaxcyte Reports Second Quarter 2022 Financial Results and Provides Business Update

-- Company Receives FDA Fast Track Designation for VAX-24 in Adults -- -- Vaxcyte Completes Successful Pre-IND Meeting with FDA Regarding VAX-24 Pediatric Program, Supporting Path to Proceed Directly into Infants --

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.

Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study

-- Company Expects to Announce Topline Results from the Phase 1 and Phase 2 Portions of the Proof-of-Concept Study in October or November 2022 -- -- Vaxcyte Also Dosed First Participants in Separate VAX-24 Phase 2 Clinical Study in Adults 65 Years and Older, With Topline Data Expected in the First Half of 2023 --

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults

Sutro Biopharma Inc

- iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering potential  new options for patients who do not respond to existing cancer immunotherapies - - Sutro will receive an upfront payment of US$90 million to develop iADCs for three biological targets and may be eligible to receive up to an additional US$422.5 million USD in development, regulatory and commercial milestones for each product candidate, plus royalties - TOKYO and SOUTH SAN FRANCISCO, Calif. , June 27, 2022 /PRNewswire/ --  Astellas Pharma Inc. (TSE: 4503), (President and CEO: Kenji Yasukawa, Ph.D.

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

-- Company Continues to Advance Phase 2 Portion of the Ongoing Phase 1/2 Clinical Proof-of-Concept Study Evaluating VAX-24 in Adults Aged 18 to 64 for the Prevention of Invasive Pneumococcal Disease and Pneumonia -- -- Announcement of Topline Safety, Tolerability and Immunogenicity Results from Both the Phase 1 and 2 Portions of the VAX-24 Phase 1/2 Study Expected by the End of 2022 --

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

SAN CARLOS, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in and host one-on-one meetings at the following investor conferences:

Vaxcyte to Participate in Upcoming Investor Conferences in May

SAN CARLOS, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET.

Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

-- Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned -- -- Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 --

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

Vaxcyte, Inc. (PCVX) CEO Grant Pickering on Q4 2021 Results - Earnings Call Transcript

-- First Participants Dosed in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults -- -- VAX-24 Phase 1/2 Study Topline Safety, Tolerability and Immunogenicity Results Expected by End of 2022 --

News for Vaxcyte Stock (PCVX)